Endocrine Abstracts

Introduction: Pregnancy in an acromegalic woman is rare and generally safe, but tumor expansion may occur. As this is a rare occurrence, little is known about the optimum management of such patients during pregnancy. We present the case of a woman with acromegaly treated with Lanreotide during pregnancy

Case report: A 29-year-old woman with acromegaly underwent transsphenoidal resection of invasive pituitary macroadenoma in August 2014, without cure. In November 2014, the IGF-1 level was 889 ng/ml (n:117 –239) and Lanreotide 120 mg was administered (s.c) every 6 weeks. In August 2015, a pregnancy in the woman was confirmed for the first time in week 14 due to irregular, rare periods. Lanreotide therapy was discontinued. In September 2015, MRI was repeated because of headache, sweating and hot flashes. The enlargement of the tumor, especially in cavernoussinus, was revealed. Lanreotide was reintroduced. The symptoms were reduced. The rest of the pregnancy was uneventful. On 29 January 2016, the patient gave birth to a healthy 2650 g son who has developed normally to date. The birth weight of her older children, born before her diagnosis, was 3200 g and 3100 g.

Conclusions: 1. Lanreotide therapy during pregnancy is safe.

2. Exposure of the fetus to Lanreotide throughout pregnancy does not induce any malformations but it can induce slight fetal growth retardation.